The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 15, 2015
Filed:
Aug. 22, 2003
Bong Cheol Kim, Gwacheon-si, KR;
MI Rim Jin, Seoul, KR;
Eun Jin Park, Seoul, KR;
Hyung Jin Jung, Seoul, KR;
Sung Seup Shin, Seoul, KR;
Jin Hwan OH, Suwon-si, KR;
Hwa Jun Lee, Seoul, KR;
Sun Young Kim, Seoul, KR;
Hyang Jeon, Seoul, KR;
Bong Cheol Kim, Gwacheon-si, KR;
Mi Rim Jin, Seoul, KR;
Eun Jin Park, Seoul, KR;
Hyung Jin Jung, Seoul, KR;
Sung Seup Shin, Seoul, KR;
Jin Hwan Oh, Suwon-si, KR;
Hwa Jun Lee, Seoul, KR;
Sun Young Kim, Seoul, KR;
Hyang Jeon, Seoul, KR;
VIROMED CO., LTD., Seoul, KR;
Abstract
The present invention provides a pharmaceutical composition comprising the extract of hardy kiwifruit as an active ingredient in an effective amount to treat and prevent allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum and reducing the level of Th2 cytokines and IgE in serum. The present invention also provides a use of above extract for the preparation of pharmaceutical composition. The present invention also provides a health food or food additives, a cosmetic composition, a feed or feed additives comprising above extract for prevention or alleviation of allergic disease and non-allergic inflammatory disease by reducing inflammation action, by inhibiting histamine release from mast cell, and by increasing the level of Th1 cytokines, IgG2a in serum, and reducing the level of Th2 cytokines and IgE in serum.